The multiple sclerosis (MS) therapy market comprises more than a dozen disease-modifying therapies (DMTs) spanning a range of mechanisms of action, clinical profiles, formulations, and value propositions. It also features substantial late-phase pipeline activity; several new candidates will be submitted and/or accepted for FDA review in 2019. DMTs in development include novel entrants (Mavenclad, an oral, short-course, selective immune reconstitution therapy), a reformulation (Biogen’s Tecfidera follow-on Vumerity), and several next-generation alternatives (e.g., Celgene’s ozanimod, Novartis’s ofatumumab). Additional areas of development include novel adjunctive neuroprotective and remyelinating strategies (e.g., MediciNova’s ibudilast, Biogen’s opicinumab), arguably the next frontier in MS treatment. This report will examine neurologists’ opinions of, receptivity to, and anticipated use of new products likely to enter this dynamic market in the next few years.
Questions Answered
Geographies: United States
Primary research: Survey of 100 neurologists
Key drugs covered: Mavenclad (oral cladribine), Vumerity (diroximel fumarate), Mayzent (siponimod), ozanimod, ibudilast, and others
Key insights provided:
Product Description
DRG’s Special Topics reports use quantitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report on multiple sclerosis will help developers gauge the competitiveness of their late-phase pipeline candidates and design messages to support or defend their market position.